IGF1R and non-small cell lung carcinoma: Indeed, beneficial effects of combining IGF-1R inhibitors with paclitaxel have been reported in non-small cell lung cancers [45–47], with topotecan in Wilms tumor cells [48], and with irinotecan in colon cancers [49, 50].